89001-57-0

Basic information

• Product Name: Benzoic acid, 5-(chlorosulfonyl)-2-methyl- (9CI)
• Synonyms: Benzoic acid, 5-(chlorosulfonyl)-2-methyl- (9CI);5-(Chlorosulphonyl)-2-methylbenzoic acid;5-(chlorosulfonyl)-2-methylbenzenecarboxylic acid;5-(Chlorosulphonyl)-o-toluic acid, 3-Carbonyl-4-methylbenzenesulphonyl chloride;5-(Chlorosulfonyl)
• CAS NO: 89001-57-0
• Molecular Formula: C₈H₇ClO₄S
• Molecular Weight: 234.65678
• Product Categories: SULFONYLHALIDE
• Mol File: 89001-57-0.mol

Chemical Properties

• Melting Point: 152-154°
• Boiling Point: 398.7 °C at 760 mmHg
• Flash Point: 194.9 °C
• Appearance: /
• Density: 1.514 g/cm³
• Vapor Pressure: 4.5E-07mmHg at 25°C
• Refractive Index: 1.576
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.57±0.25(Predicted)
• CAS DataBase Reference: Benzoic acid, 5-(chlorosulfonyl)-2-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 5-(chlorosulfonyl)-2-methyl- (9CI)(89001-57-0)
• EPA Substance Registry System: Benzoic acid, 5-(chlorosulfonyl)-2-methyl- (9CI)(89001-57-0)

Safety Data

• RIDADR: UN3261
• HazardClass: IRRITANT
• Hazardous Substances Data: 89001-57-0(Hazardous Substances Data)

Usage

Uses

5-(Chlorosulfonyl)-2-methylbenzoic acid

InChI:InChI=1/C8H7ClO4S/c1-5-2-3-6(14(9,12)13)4-7(5)8(10)11/h2-4H,1H3,(H,10,11)

Upstream product

• 118-90-1 ortho-methylbenzoic acid 
• 7790-94-5 chlorosulfonic acid 
• 95-49-8 2-methylchlorobenzene 

Relevant articles and documents

Structure-Activity Relationships of Benzamides and Isoindolines Designed as SARS-CoV Protease Inhibitors Effective against SARS-CoV-2

Inhibition of coronavirus (CoV)-encoded papain-like cysteine proteases (PLpro) represents an attractive strategy to treat infections by these important human pathogens. Herein we report on structure-activity relationships (SAR) of the noncovalent active-site directed inhibitor (R)-5-amino-2-methyl-N-(1-(naphthalen-1-yl)ethyl) benzamide (2 b), which is known to bind into the S3 and S4 pockets of the SARS-CoV PLpro. Moreover, we report the discovery of isoindolines as a new class of potent PLpro inhibitors. The studies also provide a deeper understanding of the binding modes of this inhibitor class. Importantly, the inhibitors were also confirmed to inhibit SARS-CoV-2 replication in cell culture suggesting that, due to the high structural similarities of the target proteases, inhibitors identified against SARS-CoV PLpro are valuable starting points for the development of new pan-coronaviral inhibitors.

The landscape of the anti-kinase activity of the IDH1 inhibitors

Isocitrate dehydrogenases constitute a class of enzymes that are crucial for cellular metabolism. The overexpression or mutation of isocitrate dehydrogenases are often found in leukemias, glioblastomas, lung cancers, and ductal pancreatic cancer among oth

Arylsulfonyl]-1H-indoles: Synthesis, SAR and biological evaluation as a novel class of 5-HT6 Receptor Antagonists

In continuation to our efforts to develop better treatment options for cognitive decline, we have been focussing on 5-HT6 receptor (5-HT6R) antagonists, which are known to be involved in improving cognitive function in numerous animal models. In this paper, we report a novel series of [3-[(1-Methylpiperidin-4-yl) methyl] arylsulfonyl]-1H-indole derivatives as potent and selective 5-HT6R antagonists. The lead compound from this series shows potent in vitro binding affinity, functional antagonistic activity at 5-HT6R, good pharmacokinetic profile, excellent selectivity and no Cytochrome P450 liabilities. [Figure not available: see fulltext.]

Chemoselective synthesis of aryl carboxamido sulfonic acid derivatives

A one-pot two-step synthetic strategy for the preparation of aryl carboxamido sulfonic acid derivatives was developed. The synthesis started from m-(chlorosulfonyl)benzoyl chloride, which was reacted with amines, alcohols, thiols, or sodium azide and cata

Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate

Molecules that bind selectively to a given protein and then undergo a rapid chemoselective reaction to form a covalent conjugate have utility in drug development. Herein a library of 1,3,4-oxadiazoles substituted at the 2 position with an aryl sulfonyl fluoride and at the 5 position with a substituted aryl known to have high affinity for the inner thyroxine binding subsite of transthyretin (TTR) was conceived of by structure-based design principles and was chemically synthesized. When bound in the thyroxine binding site, most of the aryl sulfonyl fluorides react rapidly and chemoselectively with the pK a-perturbed K15 residue, kinetically stabilizing TTR and thus preventing amyloid fibril formation, known to cause polyneuropathy. Conjugation t50s range from 1 to 4 min, ～1400 times faster than the hydrolysis reaction outside the thyroxine binding site. X-ray crystallography confirms the anticipated binding orientation and sheds light on the sulfonyl fluoride activation leading to the sulfonamide linkage to TTR. A few of the aryl sulfonyl fluorides efficiently form conjugates with TTR in plasma. Eleven of the TTR covalent kinetic stabilizers synthesized exhibit fluorescence upon conjugation and therefore could have imaging applications as a consequence of the environment sensitive fluorescence of the chromophore.

SUBSTITUTED PHENYLSULFAMOYL COMPOUNDS AS PPAR AGONISTS

The present invention is directed at substituted phenylsulfamoyl compounds of Formula (I), pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activa

SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS

The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

THERAPEUTIC COMPOUNDS

The present invention provides novel compounds that function as potentiators of glutamate receptors, methods for their preparation, pharmaceutical compositions containing them, and methods of their use in therapy.

ANTIBACTERIAL AGENTS

The present invention relates to antibacterial agents that are useful for sterilization, sanitation, antisepsis, and disinfection.